The USP 788 vs 789 question is one of the most frequent — and most frequently mishandled — decisions in QC laboratories testing sterile products: which chapter applies to subvisible particulate matter testing? USP <788> governs injectable preparations, while USP <789> covers ophthalmic solutions. The two chapters share the same analytical methods but differ in scope, acceptance limits and interpretation logic. Applying the wrong chapter means releasing a batch against irrelevant limits: a mistake an inspector spots within minutes. Here is a point-by-point comparison, with a side-by-side table and audit-ready guidance.
USP 788 vs 789: scope of application
USP <788> applies to parenteral preparations in general, both small-volume (SVP) and large-volume (LVP), with a few exemptions set out in the chapter itself (for example radiopharmaceuticals and products whose monograph states otherwise). With the harmonized revision that became official in 2026, the chapter — now titled Subvisible Particulate Matter in Injections — explicitly includes intramuscular and subcutaneous products in its scope.
USP <789> covers ophthalmic solutions, including those constituted from sterile solids, whenever the product monograph requires particulate testing. Ophthalmic suspensions, emulsions and gels are excluded, as are medical devices. The chapter's underlying principle is strict: ophthalmic solutions should be essentially free from particles observable on visual inspection.
The picture is completed by USP <787>, dedicated to therapeutic protein injections: it applies the same limits as <788> but with protein-specific precautions (smaller volumes, gentle handling, degassing). USP has proposed omitting it, since the harmonized <788> now also covers these products; until a final decision, the chapter remains in force.
The two methods: light obscuration and microscopy
Both chapters rely on the same two analytical procedures, described in <788> and cross-referenced by <789>:
- Method 1 — Light Obscuration (LO): electronic particle counting by light blockage. It is the first-choice method in most circumstances, thanks to its speed and direct in-solution measurement.
- Method 2 — Microscopic method: membrane filtration and counting under the microscope. It is used when LO is not applicable or yields invalid data: highly viscous, poorly transparent or colored solutions, or products that develop bubbles.
The logic is two-staged: testing starts with light obscuration and, if the result exceeds the limits, moves to the microscopic method, whose dedicated limits determine the final outcome. Going straight to the microscopic method alone is allowed only where it is documented that LO cannot be applied to the product. Very viscous solutions may be quantitatively diluted with a suitable diluent to make the test feasible.
Topics like this one — pharmacopoeial chapters, limits and audit-defensible laboratory decisions — are the bread and butter of The Pragmatic GMP, our free weekly newsletter: one practical deep dive a week, no filler theory. Subscribe so you don't miss the next ones.
Acceptance limits side by side
The most important difference between the two chapters lies in the limits. <788> expresses limits per container or per milliliter depending on the nominal volume; <789> always uses per-milliliter limits, regardless of volume, and adds a ≥50 µm size class that does not exist in <788>.
| Chapter and method | ≥10 µm | ≥25 µm | ≥50 µm |
|---|---|---|---|
| USP <788> — Method 1 (LO), containers ≤100 mL | 6,000 per container | 600 per container | — |
| USP <788> — Method 1 (LO), containers >100 mL | 25 per mL | 3 per mL | — |
| USP <788> — Method 2 (microscopic), containers ≤100 mL | 3,000 per container | 300 per container | — |
| USP <788> — Method 2 (microscopic), containers >100 mL | 12 per mL | 2 per mL | — |
| USP <789> — both methods | 50 per mL | 5 per mL | 2 per mL |
Two practical observations. First: for a 5 mL ophthalmic bottle, the <789> limits amount to 250 particles ≥10 µm in the whole container, versus the 6,000 allowed by <788> for an injectable of the same volume — ophthalmic requirements are far stricter. Second: in <789> the numerical limits of the two methods coincide, while in <788> the microscopic method has lower limits than LO, because it does not count the amorphous aggregates and semi-liquid droplets that LO detects.
The harmonized revision of USP <788>
Through the Pharmacopeial Discussion Group (PDG), USP <788> is harmonized with Ph. Eur. 2.9.19 and with chapter 6.07 of the Japanese Pharmacopoeia. The harmonized revision, official as of August 1, 2026, kept methods and limits unchanged but introduced changes that matter to the laboratory: the new title Subvisible Particulate Matter in Injections, the explicit inclusion of IM and SC products, and greater flexibility on the number of units and test volumes, provided the sampling plan is scientifically justified — a relief for low-fill biologics, for which the traditional 25 mL pooled volume was often out of reach. Laboratory SOPs should be reviewed accordingly.
Typical laboratory pitfalls
- Applying <788> limits to an ophthalmic solution: the most serious error, since the per-mL limits of <789> are much stricter.
- Forgetting the ≥50 µm class in spreadsheets and certificates of analysis for ophthalmic products.
- Air bubbles counted as particles in light obscuration: degassing and sample standing times must be defined in the SOP.
- Undocumented switch to the microscopic method: choosing Method 2 as the primary method requires evidence that LO is not applicable to the product.
- Unsuitable environment and blanks: without compliant blank controls, counts are not defensible.
- SOPs stuck at the pre-2026 version of <788>, without the new title or the sampling flexibility introduced by harmonization.
GuideGxP recommendation
Build a product applicability matrix assigning each product code the correct chapter (<788>, <789> or <787>), the primary method and the documented criteria for switching to the microscopic method, and have QA approve it: it is the fastest way to demonstrate control during an audit. Record counts as trend data, not just pass/fail outcomes: a drift in particulate levels is often the first signal of a primary-packaging or filtration issue, and the link to the Contamination Control Strategy required by Annex 1 is direct. After the 2026 revision, check that SOPs, specifications and certificates cite the chapter's current title and, if you use the new volume flexibility, formalize the scientific justification in the protocol.
To frame contamination control for sterile products within a complete framework — from the Annex 1 CCS to qualification and batch release — see the GuideGxP Operational Guide to GMP Annexes 1, 15, 16 and 20, with best practices and an operational toolkit.
